<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Summary of the joint ASCO/CAP guideline recommendations for assessment of HER2 status</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Summary of the joint ASCO/CAP guideline recommendations for assessment of HER2 status</h1>
<div class="graphic"><div class="figure"><div class="ttl">Summary of the joint ASCO/CAP guideline recommendations for assessment of HER2 status</div><div class="cntnt"><table cellspacing="0"><tbody> <tr> <td class="subtitle1_single">Optimal FISH testing requirements</td> </tr> <tr> <td class="sublist2_start">Test is rejected and repeated if:</td> </tr> <tr> <td class="sublist2">Controls are not as expected</td> </tr> <tr> <td class="sublist2">Observer cannot find and count as least two areas of invasive tumor</td> </tr> <tr> <td class="sublist2">&gt;25 percent of signals are unfavorable due to weak signals</td> </tr> <tr> <td class="sublist2">&gt;10 percent of signals occur over cytoplasm</td> </tr> <tr> <td class="sublist2">Nuclear resolution is poor</td> </tr> <tr> <td class="sublist2">Autofluorescence is strong</td> </tr> <tr> <td class="indent1">The entire ISH slide should be scanned prior to counting at least 20 cells or use IHC to define the areas of potential HER2 amplification</td> </tr> <tr> <td class="indent1">If there is a second population of cells with increased HER2 signals/cell and consists of more than 10 percent of tumor cells on the slide, a separate counting of at least 20 non-overlapping cells must also be performed with this cell population and reported</td> </tr> <tr> <td class="indent1">Counting should compare patterns in normal breast and tumor cells if bright-field ISH is used; if the tumor cell pattern is neither normal nor clearly amplified, expert opinion should be sought</td> </tr> <tr> <td class="subtitle1_single">Optimal IHC testing requirements</td> </tr> <tr> <td class="sublist2_start">Test is rejected and repeated or tested by FISH if:</td> </tr> <tr> <td class="sublist2">Controls are not as expected</td> </tr> <tr> <td class="sublist2">Artifacts involve most of sample</td> </tr> <tr> <td class="sublist2">Sample has strong membrane staining of normal breast ducts (internal controls)</td> </tr> <tr> <td class="sublist2_start">Interpretation follows guideline recommendation</td> </tr> <tr> <td class="sublist2">Positive HER2 result requires homogeneous, dark circumferential (chicken wire) pattern in &gt;10 percent of invasive tumor</td> </tr> <tr> <td class="sublist2">Interpreters have method to maintain consistency and competency</td> </tr> <tr> <td class="indent1">Sample is subjected to confirmatory FISH testing if equivocal based on initial results</td> </tr> <tr> <td class="indent1">Report must include guideline-detailed elements</td> </tr> <tr> <td class="subtitle1_single">Optimal tissue handling requirements</td> </tr> <tr> <td class="indent1">Time from tissue acquisition to fixation should be within one hour; samples from HER2 testing are fixed in 10 percent neutral buffered formalin for 6 to 72 hours; any exceptions to this process must be included in reporting</td> </tr> <tr> <td class="indent1">Samples should be sliced at 5 to 10 mm intervals after appropriate gross inspection and margins designation and placed in sufficient volume of neutral buffered formalin</td> </tr> <tr> <td class="indent1">Sections should ideally not be used for HER2 testing if cut &gt;6 weeks earlier; this may vary with primary fixation or storage conditions</td> </tr> <tr> <td class="indent1">Time to fixation and duration of fixation if available should be recorded for each sample</td> </tr> <tr> <td class="subtitle1_single">Optimal internal validation procedure</td> </tr> <tr> <td class="indent1">Validation of test must be done before test is offered</td> </tr> <tr> <td class="indent1">Laboratories performing these tests should be following all accreditation requirements</td> </tr> <tr> <td class="indent1">Initial testing validation should conform to the published 2010 ASCO/CAP recommendations for IHC testing of ER and RT guidance validation requirements with 20 negative and 20 positive FDA-approved assays and 40 negative and 40 positive for laboratory-developed tests; laboratories are responsible for ensuring the reliability and accuracy of their testing results</td> </tr> <tr> <td class="subtitle1_single">Optimal internal QA procedures</td> </tr> <tr> <td class="indent1">Initial test validation</td> </tr> <tr> <td class="indent1">Ongoing quality control and equipment maintenance</td> </tr> <tr> <td class="indent1">Initial and ongoing laboratory personnel training and competency assessment</td> </tr> <tr> <td class="indent1">Use of standard operating procedures including routine use of control materials</td> </tr> <tr> <td class="indent1">Revalidation of procedure if changed</td> </tr> <tr> <td class="indent1">Ongoing competency assessment and education of pathologists</td> </tr> <tr> <td class="subtitle1_single">Optimal external proficiency assessment</td> </tr> <tr> <td class="indent1">Participation in external proficiency testing program with at least two testing events (mailings)/year</td> </tr> <tr> <td class="sublist2_start">Satisfactory performance requires at least 90 percent correct responses on graded challenges for either test</td> </tr> <tr> <td class="sublist2">Unsatisfactory performance will require laboratory to respond according to accreditation agency program requirements</td> </tr> <tr> <td class="subtitle1_single">Optimal laboratory accreditation</td> </tr> <tr> <td class="sublist2_start">Onsite inspection every other year with annual requirement for self-inspection</td> </tr> <tr> <td class="sublist2">Reviews laboratory validation, procedures, QA results and processes, results and reports</td> </tr> <tr> <td class="sublist2">Unsatisfactory performance results in suspension of laboratory testing for HER2 for that method</td> </tr> </tbody></table></div><div class="graphic_footnotes">ASCO: American Society of Clinical Oncology; CAP: College of American Pathologists; HER2: human epidermal growth factor receptor 2; IHC: immunohistochemistry; FISH: fluorescent in situ hybridization; CEP17: chromosome 17 centromere; QA: quality assurance.</div><div class="graphic_reference">Revised with information from:<br/><ol>
<li>Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol 2013. DOI: JCO.2013.50.9984.</li>
</ol>

Modified from: Wolff AC, Hammond EH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Onc 2007; 25:118. Copyright © 2007 American Society of Clinical Oncology.</div><div id="graphicVersion">Graphic 75536 Version 7.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
